Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

2.39
+0.15506.94%
Post-market: 2.580.1900+7.95%19:59 EDT
Volume:662.92K
Turnover:1.49M
Market Cap:3.90M
PE:-0.13
High:2.39
Open:2.25
Low:2.15
Close:2.24
52wk High:71.50
52wk Low:2.15
Shares:1.63M
Float Shares:1.22M
Volume Ratio:14.27
T/O Rate:54.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:1.22
PE(LYR):-0.04

Loading ...

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

GlobeNewswire
·
Jun 25

Ernexa expects FDA review of ERNA-101 IND in Q4 2026

Reuters
·
Jun 17

Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026

THOMSON REUTERS
·
Jun 17

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

GlobeNewswire
·
Jun 17

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

GlobeNewswire
·
Jun 09

Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3

TIPRANKS
·
May 27

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

GlobeNewswire
·
May 27

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

GlobeNewswire
·
May 20

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:42 PM

Reuters
·
May 16

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM

Reuters
·
May 12

Ernexa Therapeutics announces annual shareholder meeting

Reuters
·
May 12

Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue

Reuters
·
May 12

Ernexa Therapeutics to join Virtual Investor Closing Bell event

Reuters
·
May 11

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

GlobeNewswire
·
May 11

Ernexa Therapeutics initiated with a Buy at Brookline

TIPRANKS
·
May 08

Ernexa Therapeutics announces new ERNA-101 preclinical data

TIPRANKS
·
May 07

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM

Reuters
·
May 06

Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models

Reuters
·
May 06

NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM

Reuters
·
May 03

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

GlobeNewswire
·
Apr 30